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Objectives: Metabolic syndrome (MetS) is recognised
as a reliable long-term predictor of adverse health
outcomes. Elevated prevalence rates of MetS and
chronic lifestyle diseases have been documented in
different indigenous groups. We aimed to evaluate the
prevalence of MetS and diabetes mellitus in relation to
ethnicity in Northern Norway. In addition, we discussed
different cut-off values for waist circumference (WC)
and what impact this has on the prevalence of MetS.
Materials and methods: SAMINOR is a population-
based study of health and living conditions in areas
home to Sami and non-Sami populations. The survey
was carried out in 2003–2004. All eligible residents in
specific age groups were invited. In total, 16 538 males
and females aged 36–79 years participated and gave
informed consent for medical research.
Results: This study involved a total of 7822 female
and 7290 male participants. Sami affiliation was
reported by 5141 participants (34%). The prevalence
of MetS was high in both ethnic groups independent
of which WC cut-off value was used. No ethnic
differences in prevalence of diabetes mellitus were
demonstrated. However, ethnicity appeared to affect
diabetes treatment, which was more prevalent among
Sami than non-Sami women.
Conclusions: In this study, there was no ethnic
difference in diabetes prevalence, but ethnicity appeared
to affect diabetes treatment. Tablet treatment was more
commonly in use among Sami women than among
non-Sami women. We demonstrated a high share of
negative metabolic components. These metabolic
components have important health implications.
Therefore, determining preventive initiatives is
important in the primary and specialist healthcare
system. These initiatives must be made culture and
linguistic specific, in order to reduce differences and
improve health status in the whole population.
INTRODUCTION
Chronic disease has become a global
problem and a burden on healthcare
services, reaching epidemic proportions.
In Norway, as well as internationally, the
great majority of patients in healthcare
systems are living with chronic disease.1 2
Cardiovascular disease (CVD), type 2 dia-
betes mellitus (T2DM), cancer and chronic
obstructive pulmonary disease are the most
common causes of hospitalisation and pre-
mature death.3 Unfavourable health factors
such as obesity, insulin resistance, dyslipidae-
mia and hypertension are known to elevate
risks of developing CVD and T2DM.
Metabolic syndrome (MetS) indicates a
cluster of these risk factors.4 5 MetS is gener-
ally recognised as a reliable long-term pre-
dictor of adverse health outcomes.6 Further,
MetS has been recognised as a growing,
global public health problem.7 In addition,
several studies demonstrate MetS to be asso-
ciated with elevated cancer risk.8 9
Information on the prevalence of chronic
disease in various ethnicities of North
Norway remains sparse. The Sami, Kven and
Norwegian ethnic groups have inhabited
the region for centuries; the Norwegian
government acknowledges the Sami people
as the indigenous people of Norway.
Strengths and limitations of this study
▪ The SAMINOR study is the first survey to report
on the prevalence of diabetes and metabolic syn-
drome (MetS) in a large geographic area of
North Norway including both the indigenous and
non-indigenous population.
▪ The large sample size allowed for detailed ana-
lysis of diabetes and MetS in Sami and
non-Sami populations of rural North Norway.
▪ The survey has a relatively high response rate.
▪ Categorising people based on ethnicity is a con-
tentious practice. Different studies use different
criteria of ethnicity, which makes it difficult to
compare results.
▪ Cross-sectional data cannot assess the effect of
lifestyle on the incidence of MetS, and longitu-
dinal cohort studies are, therefore, needed.
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The Norwegian health authorities have little systematic
knowledge about the health status and living conditions
among the Sami. National health and medical registers
contribute to comprehensive information and knowl-
edge about health-related lifestyle and disease preva-
lence. However, by law, information about ethnic
background is not permitted to be documented in these
registers nor in patients’ medical records. Therefore, no
reliable or updated demographic records on the Sami
exist that can be used for health research purposes.
Several epidemiological studies have documented ele-
vated prevalence rates for chronic lifestyle diseases in a
number of different minority groups.5 10 11 Although
such disorders have emerged quite recently in indigen-
ous populations—mainly due to changes in lifestyle and
diet—they are, however, prevalent in several such popu-
lations.12 13 Publications from the SAMINOR study of
North Norway demonstrate that the prevalence of
obesity was high in the survey population, especially
among Sami women.14 15
In order to evaluate the health of indigenous and
non-indigenous populations of Norway (inhabiting the
same geographic area) it was necessary to conduct an
epidemiological survey. The present study aims to evalu-
ate the prevalence of MetS and diabetes mellitus in
Sami and non-Sami populations residing in selected
areas of North Norway. In addition, we will discuss differ-
ent cut-off values for waist circumference (WC) and
what impact this has on the prevalence of MetS.
METHODS
The SAMINOR study
The cross-sectional data are derived from the SAMINOR
study from 2003 to 2004 (SAMINOR 1). The SAMINOR
study was conducted by the Centre for Sami Health
Research, Department of Community Medicine, UiT—
the Arctic University of Norway, in collaboration with the
National Screening Program for Cardiovascular Diseases.
The survey is described in detail elsewhere.16
The study sample
All eligible residents aged 30 and 36–79 years, registered
in the Central Population Register in 24 selected munici-
palities were invited regardless of ethnic background
(n=27 987). Owing to a low response rate among those
aged 30 years, our analyses were restricted to the age
interval 36–79 years (n=27 151). In total, 16 538 males
and females aged 36–79 years participated and gave
informed consent for medical research. The response
rate was 61%. Data were obtained from physical tests
and blood samples. Information on ethnicity and the
different diagnostic tools for MetS were available for
15 112 participants.
Questionnaire design
An invitation was mailed several weeks before the survey
arrived at the municipality. The invitation contained
information about the time and place of screening,
together with a five-page questionnaire. Those who
agreed to attend the screening returned the question-
naire to the Norwegian Institute of Public Health. These
participants later received an invitation to the clinical
examination. After the consultation, the participants
were asked to complete a new questionnaire.
Information regarding ethnicity, disease and lifestyle was
collected using these two self-administrated question-
naires. The questionnaires were translated into the three
main Sami languages: Northern, Lule and South Sami.
However, as only 1.6% of the participants chose to use
the Sami version of the questionnaire, any language pro-
blems are probably of little importance in this study.
Ethnicity was measured using the following questions:
‘What language(s) do/did you, your parents and your
grandparents use at home?’ The questions were to be
answered separately for each relative. The available
responses were: ‘Norwegian’, ‘Sami’, ‘Kven’ and ‘Other’.
Multiple answers were allowed. Providing the same
response options we also asked: ‘What is your, your
father’s and your mother’s ethnic background?’ The
respondents also reported whether they considered
themselves to be Norwegian, Sami, Kven or other (self-
perceived ethnicity). We refer to Lund et al16 for a full
description of the ethnicity and language questions.
Based on these variables, we generated two categories of
ethnicity: ‘Sami’ and ‘Non-Sami’. Participants reporting
at least one Sami identity mark (Sami language spoken
by the respondent or at least one parent or grandparent,
or Sami ethnic background or self-perceived Sami ethni-
city) were placed in the category ‘Sami’. The remainder
comprised the ‘Non-Sami’ participants.
Screening
Owing to the large size of the study sample, participants
were examined at different times of day. This meant that
it was not possible to ask participants to fast prior to
arrival. Non-fasting blood samples were obtained at the
research station. Blood samples were drawn by veno-
puncture at normal venous pressure, in a sitting pos-
ition. Serum was separated at the station within 1.5 h.
Serum was sent by overnight mail to laboratories in Oslo
and Tromsø. The laboratory analyses are described in
detail elsewhere.17
Body mass index (BMI) was based on measurements of
weight and height, and expressed as body weight in kilo-
grams/(body height in metres)2. BMI categories were
defined according to guidelines from the WHO; ‘under-
weight’ corresponding to a BMI<18.5 kg/m², ‘standard
weight’ in the range 18.5–24.9 kg/m², ‘overweight’ in the
range 25–29.9 kg/m² and ‘obese’ ≥30 kg/m².18
WC, which is used to identify abdominal obesity, was
measured (to the nearest centimetre) at the umbilicus,
with the participant standing erect. Two different WC
cut-off values were applied to define abdominal obe-
sity to enable the comparison of how the correspond-
ing values influenced the subsequently calculated
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prevalence of MetS. The US National Institute of Health
(NIH) Clinical Practice Guidelines defines central/
abdominal obesity as WC≥102 cm in males and
WC≥88 cm in females.19 In addition, abnormal WC for
Europid males is ≥94 cm and for females it is ≥80 cm.
These figures are based on cross-sectional data from
Europids and were included in the analyses.18 20
Trained personnel measured blood pressure (BP),
using a Dinamap—R automatic device. Measurements
were initiated after participants had been seated for
2 min with their arms resting on a table. BP was mea-
sured three times, at 1 min intervals. The mean value of
the second and third reading was used in the analysis.
Diabetes mellitus
Because all blood samples in the SAMINOR study were
non-fasting, we used random plasma glucose
≥11.1 mmol/L, in addition to self-reported diabetes and
information about antidiabetic medication from a ques-
tionnaire, to define diabetes mellitus. The question on
diabetes mellitus was: ‘Do you have or have you had dia-
betes?’ The available responses were ‘yes’ or ‘no’.
Missing values were classified as ‘no’. In the absence of
oral glucose tolerance tests, we used random plasma
glucose ≥11.1 mmol/L as a substitute for elevated oral
glucose tolerance test.
Metabolic syndrome
Several attempts have been made at developing diagnos-
tic criteria for the definition of MetS.21–23 In 2004, the
International Diabetes Federation (IDF), the WHO and
the National Cholesterol Education Program Third
Adult Treatment Panel (ATP III), produced a consensus
statement on the definition of MetS.24 The latter defin-
ition requires central obesity and cut-off points to be
specified according to gender and ethnicity. Central
obesity is most commonly measured by WC; cut-off
values are based on cross-sectional studies conducted in
Europe, the USA and Asia.18 19 20 25 The diagnostic tools
are intended for clinical and research purposes. The def-
inition of MetS used in this article adheres to the IDF
MetS worldwide definition24—central obesity plus any
two of four additional factors: elevated triglyceride level
>1.7 mmol/L, reduced HDL-cholesterol <1.03 mmol/L
in males and <1.29 mmol/L in females, elevated BP
(systolic BP≥130 or diastolic BP≥85 mm Hg) and ele-
vated fasting plasma glucose ≥11.1 mmol/L or previously
diagnosed type 2 diabetes.
Statistical analyses
All analyses were stratified by gender. Sample character-
istics were presented separately by gender and ethnicity
as mean values for continuous variables with corre-
sponding 95% CIs. Analyses of variance were used for
tests of ethnic differences (table 1). Differences accord-
ing to diabetes mellitus and MetS prevalence were tested
by χ2 tests (tables 2 and 3). MetS prevalence was also
stratified by age (table 3). Logistic regression analyses
were used to test for age influence on MetS with age as
a continuous variable (table 3).
We used the SAS statistical software package, V.9.3
(SAS Institute Inc, Cary, North Carolina, USA).
RESULTS
The current analysis involved a total of 7822 female and
7290 male participants. Sami affiliation was reported by
5141 participants (34%). Table 1 shows gender-specific
and ethnicity-specific characteristics at enrolment in the
study.
The mean BMI was greater in Sami males, whereas
the mean WC was greater in non-Sami males. Sami
females, however, showed significantly greater values for
mean BMI, WC and lipids.
Table 2 shows the prevalence of diabetes in Sami and
non-Sami participants.
No differences in prevalence of diabetes mellitus was
demonstrated between ethnic groups; however, ethnicity
appeared to affect diabetes treatment. Particularly, tablet
treatment was more commonly used among Sami women
than among non-Sami women. However, a combination
of tablet and insulin treatment was more frequently in
use among Sami men than among non-Sami men.
The prevalence of the various diagnostic tools for
MetS is presented in figures 1 (males) and 2 (females).
The most prevalent risk marker for MetS (aside from
central obesity) was the presence of elevated systolic BP
and high triglyceride levels, independent of gender and
ethnicity.
Table 3 presents the prevalence of MetS according to
WC cut-off points based on European and NIH values.
In each age bracket, the results are stratified according
to ethnicity (Sami and non-Sami). Based on the
European WC cut-off points, prevalence of MetS was
higher in non-Sami participants in the age bracket 36–
49 years. However, when applying the NIH WC cut-off
point, a significantly lower prevalence was found for
Sami males in the top age group.
Non-Sami males showed a higher overall prevalence of
MetS (in comparison with Sami males) for both WC
cut-off values. In females, ethnicity was not significant
overall; however, when stratified by age, a significantly
higher prevalence of MetS in the younger Sami females
(in comparison with non-Sami females) was found—
when applying the European WC cut-off value. The preva-
lence of MetS increased with age regardless of gender
and ethnicity. The proportion of women with all four risk
markers was almost twice as large within the Sami popula-
tion (in comparison with non-Sami females) for both WC
cut-off values (not shown). For males, ethnicity appeared
not to affect the number of risk markers found.
DISCUSSION
The prevalence of MetS was high in both ethnic groups.
No difference in prevalence of diabetes mellitus was
demonstrated between ethnic groups. It was more
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common to give treatment for diabetes to Sami men and
women than providing it to the non-Sami population.
The two different WC cut-off values greatly influenced
the measured prevalence of MetS. The present study
demonstrates that ethnicity is a significant factor for MetS
in participants belonging to the lowest age bracket.
The two different WC cut-off values greatly influenced
the measured prevalence of MetS. The present study
Table 1 Sample characteristics by gender and ethnic group (N=15 112)
Men
Sami (N=2559) Non-Sami (N=4731)
p Value*Mean (95% CI) Mean (95% CI)
Age (years) 55.0 (54.8 to 55.1) 54.8 (54.7 to 54.9) 0.584
Height (cm) 170.0 (170.0 to 170.2) 175.7 (175.6 to 175.8) <0.0001
Weight (kg) 80.6 (80.4 to 80.7) 85.1 (85.0 to 85.3) <0.0001
BMI (kg/m2) 27.8 (27.7 to 27.9) 27.5 (27.5 to 27.6) 0.009
WC (cm) 93.2 (93.0 to 93.3) 95.0 (94.9 to 95.2) <0.0001
Non-fasting glucose (mmol/L 5.8 (5.8 to 5.8) 5.8 (5.7 to 5.8) 0.313
HDL-cholesterol (mmol/L) 1.27 (1.26 to 1.28) 1.25 (1.25 to 1.26) 0.115
LDL-cholesterol (mmol/L) 3.87 (3.86 to 3.89) 3.80 (3.79 to 3.81) 0.004
Cholesterol (mmol/L) 5.98 (5.96 to 5.99) 5.90 (5.90 to 5.90) 0.001
Triglycerides (mmol/L) 1.86 (1.85 to 1.88) 1.86 (1.85 to 1.88) 0.970
Systolic BP (mm Hg) 135 (135 to 135) 134 (134 to 134) 0.168





Mean (95% CI) p Value
Age (years) 54.2 (54.1 to 54.4) 54.5 (54.4 to 54.6) 0.277
Height (cm) 157.3 (157.2 to 157.4) 162.6 (162.6 to 162.7) <0.0001
Weight (kg) 69.7 (69.6 to 69.9) 72.1 (71.9 to 72.2) <0.0001
BMI (kg/m2) 28.2 (28.1 to 28.3) 27.3 (27.2 to 27.3) <0.0001
WC (cm) 86.0 (85.9 to 86.2) 85.5 (85.4 to 85.6) 0.053
Non-fasting glucose (mmol/L 5.66 (5.63 to 5.68) 5.57 (5.55 to 5.58) 0.018
HDL-cholesterol (mmol/L) 1.45 (1.44 to 1.45) 1.49 (1.49 to 1.50) <0.0001
LDL-cholesterol (mmol/L) 3.82 (3.81 to 3.83) 3.81 (3.80 to 3.82) 0.707
Cholesterol (mmol/L) 5.98 (5.96 to 5.99) 5.99 (5.98 to 6.00) 0.617
Triglycerides (mmol/L) 1.54(1.56 to 1.59) 1.53 (1.52 to 1.54) 0.044
Systolic BP (mm Hg) 130 (129 to 130) 130 (130 to 131) 0.125
Diastolic BP (mm Hg) 72 (72 to 72) 73 (73 to 73) 0.008
*Test of differences, ANOVA, for Sami versus non-Sami.
ANOVA, analysis of variance; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; WC,
waist circumference.
Table 2 Prevalence of diabetes mellitus and diabetes treatment in the SAMINOR study (N=15 112)
Sami (N=2559) Non-Sami (N=4731)
Men n (%) n (%) p Value
Diabetes prevalence 132 (5.2) 212 (4.5) 0.19*
Insulin treatment 13 (0.5) 31 (0.7)
Tablet treatment 45 (1.8) 87 (1.8)
Insulin and tablet treatment 25 (1.0) 21 (0.4)
Non-treatment 49 (1.9) 73 (1.5)
Non-diabetes 2427 (33.3) 4519 (95.5) 0.05†
Sami (N=2581) Non-Sami (N=5241)
Women n (%) n (%) p Value
Diabetes prevalence 129 (5.0) 220 (4.2) 0.11*
Insulin treatment 13 (0.5) 29 (0.6)
Tablet treatment 61 (2.4) 71 (1.6)
Insulin and tablet treatment 20 (0.8) 38 (0.7)
Non-treatment 35 (1.4) 82 (1.6)
Non-diabetes 2452 (95.0) 5021 (95.8) 0.025†
*χ2 Test for differences in diabetes prevalence among Sami versus non-Sami.
†χ2 Test for differences in treatment level among Sami versus non-Sami.
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demonstrates that ethnicity is a significant factor for
MetS in participants belonging to the lowest age bracket.
In the case of males aged between 36 and 49 years, MetS
is less prevalent in the Sami population (in comparison
with non-Sami). For females in the same age bracket,
however, MetS is more prevalent in the Sami population.
When the NIH cut-offs were used, we found that—in the
highest age bracket—the non-Sami males showed signifi-
cantly higher prevalence of MetS in comparison with
Sami males. The prevalence of MetS increased signifi-
cantly by age in both ethnic groups, regardless of which
WC cut-off values were used.
In general, overweight and obesity were common
among the participants in the SAMINOR study. From
earlier publications based on the SAMINOR study,
central obesity has been shown to be more common in
Sami females.15 14 General obesity in Sami females has
also been discussed by Njolstad et al.26 However, obesity
rates were high in non-Sami females as well.14 For males,
central obesity occurred more frequently in the
non-Sami population relative to the Sami population.14 15
MetS has several different definitions, making it diffi-
cult to directly compare and contrast prevalence found
in different surveys. WC is the most significant measure-
ment of central obesity and fat distribution, according to
the IDF.27 The group that produced the consensus state-
ment on the definition of MetS in 2004 recommended
that gender and ethnicity should be the basis for classifi-
cation of cut-off points.24 The existing values are based
on cross-sectional population survey data from the
respective countries. How to define the WC cut-off point
in the various indigenous populations has not yet been
established; however, an immediate response would be
to perform cross-sectional population surveys within
indigenous societies. In our study, two different cut-off
points were used in order to facilitate comparison. The
European cut-off values doubled the prevalence of MetS
in males and increased prevalence by more than 40% in
Table 3 Prevalence of MetS among Sami and non-Sami, by age groups and gender (N=15 112)
Men (years)








n (%) p Value*
36–49 194 (22.3) 429 (26.0) 0.038 89 (10.2) 203 (12.3) 0.118
50–59 229 (27.2) 440 (29.7) 0.202 115 (13.7) 238 (16.1) 0.121
60–79 227 (26.9) 489 (30.6) 0.055 111 (13.1) 287 (18.0) 0.002










36–49 232 (24.4) 369 (19.1) 0.006 161 (16.2) 263 (13.6) 0.056
50–59 248 (31.5) 455 (29.4) 0.291 177 (22.5) 309 (20.0) 0.155
60–79 310 (38.7) 697 (39.6) 0.641 250 (31.2) 519 (29.5) 0.393
p Value† 0.004 <0.0001 <0.0001 <0.0001
*χ2 tests for differences in MetS prevalence of Sami versus non-Sami.
†Age effect tested by logistic regression with age as a continuous variable.
MetS, metabolic syndrome; NIH, National Institute of Health; WC, waist circumference.
Figure 1 Prevalence of different
risk markers in participants with
MetS. Men, N=2008 Euro and
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females (compared with values found when applying
NIH WC cut-off values). This was the case in both ethnic
groups. But the question of what the WC values should
be in terms of optimal prediction of prospective disease
in the SAMINOR sample remains unanswered. A
follow-up study could provide better answers to questions
regarding disease development.
Irrespective of cut-off values, elevated BP was the most
frequent MetS component present in obese participants.
These findings were also demonstrated in a collaborative
analysis of 10 large cohort studies in Europe.28 In the 10
studies included, obesity coincided with hypertension in
up to 85% of cases.
The presence of MetS, as well as its individual compo-
nents, however, shows considerable variance between
populations. Several studies of MetS have been per-
formed in circumpolar areas, such as in indigenous
peoples of Alaska, Canada and Greenland.29–31
American Indians and Aboriginal Canadians represent
populations in which MetS, obesity and T2DM are
becoming more prevalent.13 29 MetS also frequently
occurs in Greenland’s Inuit population.31 A health
survey in Greenland showed that central adiposity and
obesity were more prevalent in the Inuit population
when compared with the corresponding Danish popula-
tion, but was not associated with the same degree of
metabolic disturbance as in the general Danish popula-
tion.32 Yet, it is debatable which factors in the cluster of
MetS are the most significant in the development of
chronic lifestyle diseases.
There is a significant relation between T2DM and
MetS; the syndrome itself is not a disease, but consists of
a cluster of factors that increase the risk for developing
diseases. Thus, we prefer to include diabetes in this
article to demonstrate the link between the health indi-
cator MetS and diabetes mellitus.24 In the SAMINOR
study, diabetes mellitus was identified using a question-
naire, in addition to measured random plasma glucose
≥11.1 mmol/L in participants who did not report dia-
betes mellitus. As the study had a large number of parti-
cipants, up to 140 per day, conducting 2 h plasma
glucose tolerance tests was considered unfeasible. The
portable glycated haemoglobin (HbA1c) instruments
available in 2003–2004 were inadequate for conducting
HbA1C measurements at rural research stations. In add-
ition, the survey was performed in provincial areas at
long distances from the medical laboratory.
Our analyses do not differentiate between type 1 dia-
betes mellitus and T2DM due to insufficient information
provided by the questionnaire. However, 8 of 10 diabetes
cases in Norway are T2DM.33 Also, globally, around 80%
of diabetes cases are T2DM,34–36 giving a prevalence rate
of 8.3%. This figure is expected to increase due to life-
style changes.35 Diabetes prevalence in our study was
between 4% and 5%, which is a lower rate than the
prevalence rate found in the urban population residing
in 2007–2008 in the city of Tromsø (8.5%).37 This study
encompassed participants aged between 30 and 87 years,
with a mean age of 61 years. However, in the Tromsø
study, fasting plasma glucose, 2 h plasma glucose and
HbA1c was measured. It is therefore likely that the
present study under-reports the diabetes prevalence by
as much as up to 50%. The significance of treatment dif-
ferences between ethnic groups has not been reported
earlier and is difficult to explain. These findings will
therefore be addressed in future research.
Strengths
Our study is the first survey to report on the prevalence
of diabetes and MetS in a large geographic area of
North Norway including both the indigenous and the
non-indigenous population. The large sample size
allowed for detailed analysis of diabetes and MetS in
Sami and non-Sami populations of rural North Norway;
it also reduces the influence of random errors, which
Figure 2 Prevalence of different
risk markers in participants with
MetS. Women, N=2311 Euro and
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cannot fully be controlled for. The survey had a rela-
tively high response rate.
Unquestionably, one of the strengths of the study was
that clinical data—such as central obesity (on which
MetS relies)—were collected by direct measurement and
conducted by trained personnel, providing reliable esti-
mates of obesity prevalence in the participating cohort.
Limitations
The cross-sectional study design is suitable for the exam-
ination of associations in order to generate hypotheses
that may be explored in longitudinal studies. Conversely,
however, the design prevents the establishment of causal-
ity. Owing to the nature of the design, people with
severe disease may be missed because they are either dis-
eased at home or in long-term hospitalisation, or have
died in the time since the sample list was prepared (ie,
selection bias). The SAMINOR study has used question-
naires to survey self-reported diseases. This approach
cannot detect people with undiagnosed symptoms and is
limited by recall bias. In Norway, it is estimated that
between 9000 and 120 000 people have diabetes and
nearly as many have undiagnosed disease.38
Categorising people based on ethnicity is a conten-
tious practice. Different studies use different criteria of
ethnic categorisation, which makes it difficult to
compare results. Our definition of the Sami group is
rather weak. This may have influenced our results. Since
there are no national records with information on
ethnic background, it is impossible to know if the
response rates among Sami and non-Sami are different.
We are therefore unable to assess whether differences in
participation have influenced the observed disease
burden.
In summary, cross-sectional studies may be used in the
measurement of the burden of disease in a population.
However, cross-sectional data cannot assess the effect of
lifestyle on the incidence of MetS, and longitudinal
cohort studies are therefore needed.
CONCLUSION
Without question, the prevalence rates for several nega-
tive health factors were high in the Sami and non-Sami
populations. Overweight and obesity were common,
especially in the case of Sami females. No difference in
prevalence of diabetes mellitus was demonstrated
between the ethnic groups. However, ethnicity appeared
to affect diabetes treatment and was significantly more
frequently in use among Sami women than among
non-Sami women. However, the prevalence of MetS was
generally high among participants in the SAMINOR
study, with the highest prevalence for the European
cut-off values. The syndrome has important health impli-
cations, but a cross-sectional study cannot be used to val-
idate the best ethnicity-specific values for WC used in
the definition of MetS and more data on this issue must
be obtained. In addition, determining preventive
initiatives is important in the primary and specialist
healthcare system. These initiatives must be made
culture and linguistic specific, in order to reduce differ-
ences and improve health status in the whole
population.
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